NBIX vs. UTHR

Last updated Apr 2, 2026

Compare and contrast key facts about Neurocrine Biosciences, Inc. (NBIX) and United Therapeutics Corporation (UTHR).

Performance

NBIX vs. UTHR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Neurocrine Biosciences, Inc. (NBIX) and United Therapeutics Corporation (UTHR). The values are adjusted to include any dividend payments, if applicable.

NBIX vs. UTHR - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NBIX Neurocrine Biosciences, Inc.	-6.54%	3.90%	3.60%	10.31%	40.24%	-11.14%	-10.83%	50.53%	-7.96%	100.49%
UTHR United Therapeutics Corporation	17.04%	38.09%	60.46%	-20.93%	28.70%	42.35%	72.33%	-19.12%	-26.39%	3.15%

Fundamentals

Market Cap NBIX : $13.59B UTHR : $27.32B
EPS NBIX : $4.69 UTHR : $27.90
PE Ratio NBIX : 28.25 UTHR : 20.44
PEG Ratio NBIX : 0.56 UTHR : 0.67
PS Ratio NBIX : 4.73 UTHR : 8.57
PB Ratio NBIX : 4.18 UTHR : 3.85
Total Revenue (TTM) NBIX : $2.86B UTHR : $3.18B
Gross Profit (TTM) NBIX : $2.81B UTHR : $2.80B
EBITDA (TTM) NBIX : $719.10M UTHR : $1.82B

Returns By Period

In the year-to-date period, NBIX achieves a -6.54% return, which is significantly lower than UTHR's 17.04% return. Over the past 10 years, NBIX has underperformed UTHR with an annualized return of 12.30%, while UTHR has yielded a comparatively higher 17.58% annualized return.

NBIX

• 1D: 0.62%
• 1M: 0.14%
• YTD: -6.54%
• 6M: -3.24%
• 1Y: 23.89%
• 3Y*: 9.41%
• 5Y*: 6.19%
• 10Y*: 12.30%

UTHR

• 1D: -3.83%
• 1M: 10.99%
• YTD: 17.04%
• 6M: 30.15%
• 1Y: 85.83%
• 3Y*: 36.55%
• 5Y*: 24.28%
• 10Y*: 17.58%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NBIX vs. UTHR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NBIX

NBIX Risk / Return Rank: 61
NBIX Sharpe Ratio Rank: 66
NBIX Sortino Ratio Rank: 58
NBIX Omega Ratio Rank: 60
NBIX Calmar Ratio Rank: 61
NBIX Martin Ratio Rank: 62

UTHR

UTHR Risk / Return Rank: 91
UTHR Sharpe Ratio Rank: 87
UTHR Sortino Ratio Rank: 92
UTHR Omega Ratio Rank: 92
UTHR Calmar Ratio Rank: 94
UTHR Martin Ratio Rank: 92

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NBIX vs. UTHR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and United Therapeutics Corporation (UTHR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NBIX	UTHR	Difference
Sharpe ratio Return per unit of total volatility	0.71	1.71	-0.99
Sortino ratio Return per unit of downside risk	1.13	3.11	-1.98
Omega ratio Gain probability vs. loss probability	1.16	1.43	-0.27
Calmar ratio Return relative to maximum drawdown	0.95	5.20	-4.25
Martin ratio Return relative to average drawdown	2.31	13.21	-10.90
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NBIX vs. UTHR - Sharpe Ratio Comparison

The current NBIX Sharpe Ratio is 0.71, which is lower than the UTHR Sharpe Ratio of 1.71. The chart below compares the historical Sharpe Ratios of NBIX and UTHR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NBIX	UTHR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.71	1.71	-0.99
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.19	0.69	-0.50
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.31	0.50	-0.19
Sharpe Ratio (All Time) Calculated using the full available price history	0.13	0.39	-0.26

Correlation

The correlation between NBIX and UTHR is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NBIX vs. UTHR - Dividend Comparison

Neither NBIX nor UTHR has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

NBIX vs. UTHR - Drawdown Comparison

The maximum NBIX drawdown since its inception was -97.21%, roughly equal to the maximum UTHR drawdown of -93.18%. Use the drawdown chart below to compare losses from any high point for NBIX and UTHR.

Drawdown Indicators

	NBIX	UTHR	Difference
Max Drawdown Largest peak-to-trough decline	-97.21%	-93.18%	-4.03%
Max Drawdown (1Y) Largest decline over 1 year	-20.90%	-16.35%	-4.55%
Max Drawdown (5Y) Largest decline over 5 years	-42.89%	-33.00%	-9.89%
Max Drawdown (10Y) Largest decline over 10 years	-46.39%	-55.56%	+9.17%
Current Drawdown Current decline from peak	-14.82%	-3.83%	-10.99%
Average Drawdown Average peak-to-trough decline	-44.05%	-35.52%	-8.53%
Ulcer Index Depth and duration of drawdowns from previous peaks	8.59%	6.43%	+2.16%

Volatility

NBIX vs. UTHR - Volatility Comparison

The current volatility for Neurocrine Biosciences, Inc. (NBIX) is 6.97%, while United Therapeutics Corporation (UTHR) has a volatility of 17.27%. This indicates that NBIX experiences smaller price fluctuations and is considered to be less risky than UTHR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NBIX	UTHR	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.97%	17.27%	-10.30%
Volatility (6M) Calculated over the trailing 6-month period	23.03%	27.12%	-4.09%
Volatility (1Y) Calculated over the trailing 1-year period	33.89%	50.58%	-16.69%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	32.22%	35.31%	-3.09%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	39.43%	35.33%	+4.10%

Financials

NBIX vs. UTHR - Profitability Comparison

The chart below illustrates the profitability comparison between Neurocrine Biosciences, Inc. and United Therapeutics Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

NBIX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported a gross profit of 787.90M and revenue of 805.50M. Therefore, the gross margin over that period was 97.8%.

UTHR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, United Therapeutics Corporation reported a gross profit of 686.80M and revenue of 790.20M. Therefore, the gross margin over that period was 86.9%.

NBIX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported an operating income of 210.90M and revenue of 805.50M, resulting in an operating margin of 26.2%.

UTHR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, United Therapeutics Corporation reported an operating income of 356.70M and revenue of 790.20M, resulting in an operating margin of 45.1%.

NBIX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported a net income of 153.70M and revenue of 805.50M, resulting in a net margin of 19.1%.

UTHR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, United Therapeutics Corporation reported a net income of 364.30M and revenue of 790.20M, resulting in a net margin of 46.1%.